Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec to remain independent

Biogen Idec to remain independent

17th December 2007

Biogen Idec has reported that its board of directors has completed its review of the strategic alternatives open to the firm and decided that it will remain an independent company.

This announcement follows a process started in October 2007 to assess the potential value for stockholders of a strategic interest on the part of major pharmaceutical firms, with Biogen Idec completing a comprehensive sale process to make this decision.

Biogen Idec has reiterated the goals of its current business plan, which include having 100,000 patients treated with Tysabri (natalizumab) by the end of 2010, while also having over 40 per cent of its revenue from international business with a revenue growth of 15 per cent.

“The board emphasized that Biogen Idec’s business strategy is working and generating strong operating and financial performance,” the company said.

“The board noted that it is confident that continued execution of the company’s business plan will result in attractive value for stockholders.”

Biogen Idec is also aiming for four new products or existing products launched by the end of 2010, as well as having six programmes in the later stages of clinical development.

In August 2007, Biogen Idec announced the appointment of Paul Clancy to the position of executive vice-president and chief financial officer of the firm.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.